Elicera Therapeutics AB is a clinical stage immuno-oncology company that specializes in developing advanced cell and gene therapies for immune-based cancer treatments. Their innovative approach focuses on harnessing the power of the immune system to effectively combat cancer. With a strong portfolio of products and services, Elicera Therapeutics aims to revolutionize cancer treatment.

Their research and development efforts have resulted in the creation of four groundbreaking drug candidates. Two of these candidates are based on oncolytic viruses, such as the clinically-studied ELC-100 (AdVince), which shows promise in the treatment of neuroendocrine tumors. The other two candidates are based on CAR T-cell therapy, with ELC-301 being developed to target B-cell lymphoma.

In addition to their cutting-edge drug candidates, Elicera Therapeutics has also developed an innovative platform technology called iTANK (Immunotherapies Activated with Nap for efficient Killing). This platform aims to enhance the immune response and improve the effectiveness of treatments in the fields of oncolytic viruses and CAR T-cell therapies. Elicera Therapeutics is dedicated to advancing the field of immuno-oncology and delivering effective and personalized treatments for cancer patients.

With a team of experienced professionals and a strong commitment to scientific excellence, they are well-positioned to make significant contributions to the fight against cancer